Financial News
FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says
December 30, 2022 at 11:21 AM EST
A report by two House committees found that the Food and Drug Administration's controversial approval of the Alzheimer's drug Aduhelm was "rife with irregularities."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
